Free Trial

BioMarin Pharmaceutical (BMRN) Competitors

BioMarin Pharmaceutical logo
$57.41 -0.09 (-0.16%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$57.86 +0.46 (+0.79%)
As of 09:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BMRN vs. BIIB, INCY, UTHR, NBIX, EXEL, EXAS, RGEN, MDGL, HALO, and IONS

Should you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry.

BioMarin Pharmaceutical vs. Its Competitors

Biogen (NASDAQ:BIIB) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Biogen has higher revenue and earnings than BioMarin Pharmaceutical. Biogen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.68B1.97$1.63B$10.1312.85
BioMarin Pharmaceutical$2.85B3.86$426.86M$2.6921.34

BioMarin Pharmaceutical has a net margin of 17.76% compared to Biogen's net margin of 15.07%. Biogen's return on equity of 14.03% beat BioMarin Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen15.07% 14.03% 8.32%
BioMarin Pharmaceutical 17.76%11.34%8.95%

Biogen has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500.

In the previous week, Biogen and Biogen both had 9 articles in the media. BioMarin Pharmaceutical's average media sentiment score of 0.87 beat Biogen's score of 0.75 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
5 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioMarin Pharmaceutical
5 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Biogen presently has a consensus price target of $188.48, indicating a potential upside of 44.84%. BioMarin Pharmaceutical has a consensus price target of $93.61, indicating a potential upside of 63.05%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
0 Sell rating(s)
20 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.38
BioMarin Pharmaceutical
0 Sell rating(s)
6 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.75

87.9% of Biogen shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 0.9% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

BioMarin Pharmaceutical beats Biogen on 11 of the 15 factors compared between the two stocks.

Get BioMarin Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMRN vs. The Competition

MetricBioMarin PharmaceuticalMED IndustryMedical SectorNASDAQ Exchange
Market Cap$11.03B$2.91B$5.51B$9.02B
Dividend YieldN/A2.44%5.24%4.05%
P/E Ratio21.3420.4427.2120.09
Price / Sales3.86190.28370.4792.99
Price / Cash17.7141.7026.2128.59
Price / Book1.937.397.945.55
Net Income$426.86M-$55.04M$3.17B$248.49M
7 Day Performance2.17%2.51%1.79%4.87%
1 Month Performance1.34%-0.21%1.27%6.63%
1 Year Performance-30.56%3.41%33.56%20.38%

BioMarin Pharmaceutical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMRN
BioMarin Pharmaceutical
4.9377 of 5 stars
$57.41
-0.2%
$93.61
+63.1%
-29.5%$11.03B$2.85B21.343,040
BIIB
Biogen
4.9185 of 5 stars
$125.59
-0.4%
$188.48
+50.1%
-42.3%$18.40B$9.68B12.407,605
INCY
Incyte
4.8046 of 5 stars
$68.10
-0.4%
$74.53
+9.4%
+17.3%$13.18B$4.24B212.822,617Trending News
Insider Trade
UTHR
United Therapeutics
4.9946 of 5 stars
$287.35
+1.1%
$386.15
+34.4%
-7.7%$12.96B$2.88B11.471,305Positive News
NBIX
Neurocrine Biosciences
4.9139 of 5 stars
$125.69
+0.2%
$162.00
+28.9%
-8.1%$12.44B$2.36B42.611,800Positive News
Insider Trade
EXEL
Exelixis
4.73 of 5 stars
$44.08
+0.9%
$43.56
-1.2%
+99.8%$12.02B$2.17B20.041,147Positive News
Options Volume
EXAS
Exact Sciences
4.9338 of 5 stars
$53.14
-1.0%
$70.40
+32.5%
+17.7%$10.02B$2.83B-9.647,000Positive News
RGEN
Repligen
4.7608 of 5 stars
$124.38
+0.7%
$172.83
+39.0%
+3.6%$6.99B$634.44M-276.401,778
MDGL
Madrigal Pharmaceuticals
4.0638 of 5 stars
$302.64
+0.6%
$420.63
+39.0%
+4.6%$6.72B$317.38M-16.7790
HALO
Halozyme Therapeutics
4.7663 of 5 stars
$52.02
-0.4%
$61.90
+19.0%
+5.2%$6.41B$1.02B13.84390High Trading Volume
IONS
Ionis Pharmaceuticals
4.6553 of 5 stars
$39.51
-0.7%
$57.88
+46.5%
-9.4%$6.29B$705M-13.211,069

Related Companies and Tools


This page (NASDAQ:BMRN) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners